# Efficacy and Safety of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD)

> **NCT05551598** · PHASE2 · COMPLETED · sponsor: **CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.** · enrollment: 46 (actual)

## Conditions studied

- Neuromyelitis Optica Spectrum Disorder

## Interventions

- **DRUG:** Mitoxantrone Hydrochloride Liposome Injection

## Key facts

- **NCT ID:** NCT05551598
- **Lead sponsor:** CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-11-28
- **Primary completion:** 2024-07-18
- **Final completion:** 2024-07-18
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2024-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05551598

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05551598, "Efficacy and Safety of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05551598. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*